The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Bispecific antibodies
Bispecific antibodies
Bispecific antibodies recognize two distinct targets (antigens) expressed on cells, enhancing the activity for cancer immunotherapy. There may be different applications, such as targeting different antigens on a single tumor cell or binding to both a cancer cell and a T cell, bringing them in closer contact to each other. The aim is to increase the antitumor activity and reduce the chances of developing resistance. Bispecific antibodies, like AMV564 and AMG 330, are in development in AML.
|
|